INDP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	8 071.00
Average Volume	87 090.00
Market Cap	18.02M
EPS	$-0.476 ( 2024-03-15 )
Next earnings date	( $-0.540 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.150
ATR14	$0.0260 (1.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Linscott Walt Addison	Buy	75 000	Stock Option (Right to Buy)
2024-01-22	Waltzman Roger J.	Buy	75 000	Stock Option (Right to Buy)
2024-01-22	Sassi Nir	Buy	40 000	Stock Option (Right to Buy)
2024-01-22	Meckler Jeffrey A	Buy	100 000	Stock Option (Right to Buy)
2024-01-22	Newman Michael James	Buy	43 250	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 90 transactions
Buy: 2 551 706 \| Sell: 72 874

Indaptus Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Indaptus Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1 284.00 (0.00 %)
EPS:	$-1.840

FY	2023
Revenue:	$0
Gross Profit:	$-1 284.00 (0.00 %)
EPS:	$-1.840

FY	2022
Revenue:	$0
Gross Profit:	$-1 781.00 (0.00 %)
EPS:	$-1.660

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.890

Financial Reports:

No articles found.

Indaptus Therapeutics,

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.